Floatz logo

HR20013

Chemotherapy-Induced Toxicity

Fujian Shengdi Pharmaceutical Co., Ltd.UNKNOWNPhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

62 Active assets in the Chemotherapy-Induced Toxicity cohort.

Asset / SponsorPhaseRating
Palonosetron
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4A
Dexasone
Instituto do Cancer do Estado de São Paulo
Phase 4A
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Docetaxel
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BB
Netupitant
Instituto Brasileiro de Controle do Cancer
Phase 3BB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →